Teaming up with the Healey & AMG Center, Inflammasome will advance its oral ALS drug kamuvudine-9, known as K9, into early clinical testing.

Transition Bio and Voyager have teamed to discover and develop new small molecules that target toxic TDP-43 protein clumps in ...

Oprah's interview with Emma Heming Willis resonated with columnist Kristin Neva, who reflects on life as an ALS caregiver.

A brain-computer interface capable of decoding Mandarin Chinese from brain signals may help people with paralysis or ALS to ...

The ALS prevalence is expected to rise across multiple nations by 2040 due to aging populations and increased ALS survival ...

Columnist Juliet Taylor discusses the Tim Lowrey ALS Panel Series, which has provided tailored information to 1,500 people ...

Preclinical data showed imaging agent ACI-19626 can selectively bind to abnormal clumps of the TDP-43 protein, a hallmark of ...

These days, columnist Dagmar Munn is all about manipulating the algorithm of her brain to improve her outlook and turn down ...

For guest writer Nancy Muirhead, dealing with food and beverages has become unpleasant due to ALS. She's decided to get a PEG ...

Researchers in Germany say combining two blood biomarkers may make the diagnosis of ALS more accurate and help predict ...

The Packard Center and ALS United will fund a preclinical study investigating how abnormal TDP-43 protein contributes to ALS.

Patient enrollment is complete in a Phase 2b/3 clinical trial evaluating MN-166 (ibudilast), an investigational oral therapy developed by Medicinova to treat amyotrophic lateral sclerosis (ALS). The ...